# Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

Study · id `cardio:ct-nct07028749` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07028749](<https://clinicaltrials.gov/study/NCT07028749>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07028749

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 316 participants.

## Technical summary

Registry record NCT07028749. Randomized; quadruple masking; primary purpose treatment. Start 2025-06-30 (actual); primary completion 2027-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 316 participants (planned count; ClinicalTrials.gov record NCT07028749, source copy `cardio:ctgov-nct07028749-2026-09-02`, retrieved 2026-11-18)
- Started: 2025-06-30 (actual) (ClinicalTrials.gov record NCT07028749, source copy `cardio:ctgov-nct07028749-2026-09-02`, retrieved 2026-11-18)
- Primary completion: 2027-11 (anticipated) (ClinicalTrials.gov record NCT07028749, source copy `cardio:ctgov-nct07028749-2026-09-02`, retrieved 2026-11-18)
- Completion: 2028-04 (anticipated) (ClinicalTrials.gov record NCT07028749, source copy `cardio:ctgov-nct07028749-2026-09-02`, retrieved 2026-11-18)
- Countries: United States; Australia; Canada; New Zealand (ClinicalTrials.gov record NCT07028749, source copy `cardio:ctgov-nct07028749-2026-09-02`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07028749-2026-09-02`, retrieved 2026-11-18)

## The registry's words

- Brief title: Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
- Acronym: TYDAL-TIMI 78
- Condition: Hypertriglyceridemia
- Intervention (Drug): MAR001
- Intervention (Drug): Placebo
- Lead sponsor: Marea Therapeutics
- Lead sponsor class: INDUSTRY
- Collaborator: The TIMI Study Group
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as a collaborator: The TIMI Study Group (`cardio:org-the-timi-study-group`)

## Provenance

Content hash: 55f9ca6f3baf63187c50e9c3199a16323d6b9bbf737f9414eae3239ec66b5974
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
